Progress in cancer therapy targeting c-Met signaling pathway

Archives of Pharmacal Research

Volumn 35, Issue 4, 2012, Pages 595-604

  Jung, Kyung Hee ^a   Park, Byung Hee ^a   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

C Met; Cancer; Cancer drug development; Hepatocyte growth factor (HGF); Proliferation; Receptor tyrsine kinase; Signal transduction

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMUVATINIB; ANTINEOPLASTIC AGENT; C MET INHIBITOR; CABOZANTINIB; CRIZOTINIB; FICLATUZUMAB; FORETINIB; GOLVATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TIVANTINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENICITY; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84862893807     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0402-6     Document Type: Review

References (56)

1. Bean, J., Brennan, C., Shih, J. Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., Balak, M., Chang, W. C., Yu, C. J., Gazdar, A., Pass, H., Rusch, V., Gerald, W., Huang, S. F., Yang, P. C., Miller, V., Ladanyi, M., Yang, C. H., and Pao, W., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A., 104, 20932-20937 (2007).
2. Birchmeier, C. and Gherardi, E., Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol., 8, 404-410 (1998).
3. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G. F., Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 4, 915-925 (2003).
4. Boccaccio, C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., and Comoglio, P. M., Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 391, 285-288 (1998).
5. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., and Aaronson, S. A., Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 251, 802-804 (1991).
6. Buchanan, S. G., Hendle, J., Lee, P. S., Smith, C. R., Bounaud, P. Y., Jessen, K. A., Tang, C. M., Huser, N. H., Felce, J. D., Froning, K. J., Peterman, M. C., Aubol, B. E., Gessert, S. F., Sauder, J. M., Schwinn, K. D., Russell, M., Rooney, I. A., Adams, J., Leon, B. C., Do, T. H., Blaney, J. M., Sprengeler, P. A., Thompson, D. A., Smyth, L., Pelletier, L. A., Atwell, S., Holme, K., Wasserman, S. R., Emtage, S., Burley, S. K., and Reich, S. H., SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther., 8, 3181-3190 (2009).
7. Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., Chen, Q., Ho, S. Y., Li, L., Kaufman, S., McDorman, K., Cattley, R. C., Elliott, G., Zhang, K., Feng, X., Jia, X. C., Green, L., Radinsky, R., and Kendall, R., Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res., 66, 1721-1729 (2006).
8. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R., Lipson, K. E., Ramphal, J., Do, S., Cui, J. J., Cherrington, J. M., and Mendel, D. B., A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res., 63, 7345-7355 (2003).
9. Christensen, J. G., Burrows, J., and Salgia, R., c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett., 225, 1-26 (2005).
10. Comoglio, P. M., Giordano, S., and Trusolino, L., Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov., 7, 504-516 (2008).
11. De Bacco, F., Luraghi, P., Medico, E., Reato, G., Girolami, F., Perera, T., Gabriele, P., Comoglio, P. M., and Boccaccio, C., Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst., 103, 645-661 (2010).
12. Di Renzo, M. F., Narsimhan, R. P., Olivero, M., Bretti, S., Giordano, S., Medico, E., Gaglia, P., Zara, P., and Comoglio, P. M., Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene, 6, 1997-2003 (1991).
13. Eder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H., Cancilla, B., Chu, F., Hitchcock-Bryan, S., Sherman, L., McCallum, S., Heath, E. I., Boerner, S. A., and LoRusso, P. M., A phase I study of foretinib, a multitargeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res., 16, 3507-3516 (2010).
14. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., and Janne, P. A., c-MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-1043 (2007).
15. Fischer, O. M., Giordano, S., Comoglio, P. M., and Ullrich, A., Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem., 279, 28970-28978 (2004).
16. Follenzi, A., Bakovic, S., Gual, P., Stella, M. C., Longati, P., and Comoglio, P. M., Cross-talk between the proto-oncogenes Met and Ron. Oncogene, 19, 3041-3049 (2000).
17. Gherardi, E. and Stoker, M., Hepatocytes and scatter factor. Nature, 346, 228 (1990).
18. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., and Stratton, M. R., Patterns of somatic mutation in human cancer genomes. Nature, 446, 153-158 (2007).
19. Guessous, F., Zhang, Y., diPierro, C., Marcinkiewicz, L., Sarkaria, J., Schiff, D., Buchanan, S., and Abounader, R., An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med. Chem., 10, 28-35 (2010).
20. Jun, H. T., Sun, J., Rex, K., Radinsky, R., Kendall, R., Coxon, A., and Burgess, T. L., AMG 102, a fully human antihepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res., 13, 6735-6742 (2007).
21. Karamouzis, M. V., Konstantinopoulos, P. A., and Papavassiliou, A. G., Trastuzumab-mechanism of action and use. N. Engl. J. Med., 357, 1664; author reply 1665-1666 (2007).
22. Khoury, H., Naujokas, M. A., Zuo, D., Sangwan, V., Frigault, M. M., Petkiewicz, S., Dankort, D. L., Muller, W. J., and Park, M., HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell, 16, 550-561 (2005).
23. Kim, K. J., Wang, L., Su, Y. C., Gillespie, G. Y., Salhotra, A., Lal, B., and Laterra, J., Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res., 12, 1292-1298 (2006).
24. Knudsen, B. S. and Vande Woude, G., Showering c-METdependent cancers with drugs. Curr. Opin. Genet. Dev., 18, 87-96 (2008).
25. Kong-Beltran, M., Stamos, J., and Wickramasinghe, D., The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell, 6, 75-84 (2004).
26. Kovacs, G., Molecular cytogenetics of renal cell tumors. Adv. Cancer Res., 62, 89-124 (1993).
27. Lamorte, L., Kamikura, D. M., and Park, M., A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene, 19, 5973-5981 (2000).
28. Laux I., Phase I dose escalation trial (ARQ197-111) evaluating combination of selective c-Met inhibitor ARQ197 and erlotinib. The AACR Annual Meeting, Abstract 3549 (2009).
29. Lee, C. C., Putnam, A. J., Miranti, C. K., Gustafson, M., Wang, L. M., Vande Woude, G. F., and Gao, C. F., Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene, 23, 5193-5202 (2004).
30. Liu, X., Yao, W., Newton, R. C., and Scherle, P. A., Targeting the c-MET signaling pathway for cancer therapy. Expert Opin. Investig. Drugs, 17, 997-1011 (2008).
31. Liu, X., Newton, R. C., and Scherle, P. A., Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med., 16, 37-45 (2010).
32. Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., Seiwert, T., Christensen, J. G., Jagadeeswaran, R., Krausz, T., Vokes, E. E., Husain, A. N., and Salgia, R., Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer, 47, 1025-1037 (2008).
33. Ma, W. W. and Adjei, A. A., Novel agents on the horizon for cancer therapy. CA Cancer J. Clin., 59, 111-137 (2009).
34. Martens, T., Schmidt, N. O., Eckerich, C., Fillbrandt, R., Merchant, M., Schwall, R., Westphal, M., and Lamszus, K., A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res., 12, 6144-6152 (2006).
35. Matsumoto, K. and Nakamura, T., Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem. Biophys. Res. Commun., 333, 316-327 (2005).
36. Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., Comoglio, P. M., and Michieli, P., An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest., 114, 1418-1432 (2004).
37. Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., and Comoglio, P. M., Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 6, 61-73 (2004).
38. Munshi, N., Jeay, S., Li, Y., Chen, C. R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., Li, and C. J., ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther., 9, 1544-1553 (2010).
39. Naldini, L., Weidner, K. M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., Narsimhan, R. P., Hartmann, G., Zarnegar, R., and Michalopoulos, G. K., Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J., 10, 2867-2878 (1991).
40. Pelicci, G., Giordano, S., Zhen, Z., Salcini, A. E., Lanfrancone, L., Bardelli, A., Panayotou, G., Waterfield, M. D., Ponzetto, C., and Pelicci, P. G., The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene, 10, 1631-1638 (1995).
41. Petrelli, A., Circosta, P., Granziero, L., Mazzone, M., Pisacane, A., Fenoglio, S., Comoglio, P. M., and Giordano, S., Abinduced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. U. S. A., 103, 5090-5095 (2006).
42. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M., A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 77, 261-271 (1994).
43. Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K. A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., Lougheed, J., Yakes, F. M., Bentzien, F., Xu, W., Zaks, T., Wooster, R., Greshock, J., and Joly, A. H., Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res., 69, 4408-4417 (2009)
44. Recio, J. A. and Merlino, G., Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene, 21, 1000-1008 (2002).
45. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., and Comb, M. J., Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 131, 1190-1203 (2007).
46. Rodrigues, G. A., Park, M., and Schlessinger, J., Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J., 16, 2634-2645 (1997).
47. Rosen, L. S., Senzer, N., Mekhail, T., Ganapathi, R., Chai, F., Savage, R. E., Waghorne, C., Abbadessa, G., Schwartz, B., and Dreicer, R., A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin. Cancer Res., 17, 7754-7764 (2011).
48. Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., and Haber, D. A., Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U. S. A., 103, 2316-2321 (2006).
49. Sonnenberg, E., Meyer, D., Weidner, K. M., and Birchmeier, C., Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol., 123, 223-235 (1993).
50. Stella, M. C., Trusolino, L., Pennacchietti, S., and Comoglio, P. M., Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell. Biol., 25, 3982-3996 (2005).
51. Trusolino, L., Bertotti, A., and Comoglio, P. M., MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol., 11, 834-848 (2010).
52. Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., Daikuhara, Y., and Birchmeier, W., Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. U. S. A., 88, 7001-7005 (1991).
53. Yap, T. A., Olmos, D., Brunetto, A. T., Tunariu, N., Barriuso, J., Riisnaes, R., Pope, L., Clark, J., Futreal, A., Germuska, M., Collins, D., deSouza, N. M., Leach, M. O., Savage, R. E., Waghorne, C., Chai, F., Garmey, E., Schwartz, B., Kaye, S. B., de, and Bono, J. S., Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol., 29, 1271-1279 (2011).
54. Zhang, Y. W., Wang, L. M., Jove, R., and Vande Woude, G. F., Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene, 21, 217-226 (2002).
55. Zhuang, Z., Park, W. S., Pack, S., Schmidt, L., Vortmeyer, A. O., Pak, E., Pham, T., Weil, R. J., Candidus, S., Lubensky, I. A., Linehan, W. M., Zbar, B., and Weirich, G., Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat. Genet., 20, 66-69 (1998).
56. Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P. P., Nambu, M. D., Los, G., Bender S. L., Mroczkowski, B., and Christensen, J. G., An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 67, 4408-4417 (2007).